Content Library
Past Presentations, Reports and Interviews by Leading Industry Experts.
|
|
ADC London Post Event Report |
|
|
Meet the Speakers at World ADC London 2019 |
|
|
Antibody Drug Conjugates Clinical E-Book |
|
|
Getting Small to Enhance Targeting: Non-Internalizing Small Molecule-Drug Conjugates for the Treatment of Solid TumoursSamuele Cazzamalli |
|
|
Screening for ADC Biotransformations Using Mass SpectrometryConnor Barry
|
|
|
Bispecific ADCs Bridging HER2 and Proclactin ReceptorJulian Andreev
|
 |
MAM Workflow Customer Facing Presentation |
 |
World ADC San Diego Post Event Report 2017 |
 |
Clinical Development of ADC-IO Combinations: Today and TomorrowJay Harper, Ph.D., MedImmune Oncology Research |
 |
Antibody Drug Conjugates: Process Development and Analytical ConsiderationsMichael Hay – Bristol-Myers Squibb |
 |
Immunogenicity Assay Strategies for Antibody-Drug ConjugatesSeema Kumar, PhD, EMD Serono Research & Development Institute |
 |
Clinical Development of ADCs: ARX788, a Her2-targeting ADC as an Example – AmbrxYong-jiang Hei, M.D., Ph.D. Download Here |
|
|
Linker Design: Why so complex? – GNFBernhard Geierstanger Download Here |
|
|
New cryptophycins as promising payloads for ADC – SanofiHervé Bouchard |
|
|
Pall Life Sciences White PaperNew Genderless Sterile Connection Technology – A Quality By Design (QbD) Approach For Greater Sterility Assurance From Manufacturing To Use |
|
|
Regulatory perspective for successful antibody-drug conjugate developmentWen Jin Wu |
|
|
CD19 ADCs Effectively Targeting B Cell Malignancies – a clinical perspective.Martin J.S. Dyer |
|
|
CD19 ADCs Effectively Targeting B Cell Malignancies – a clinical perspective.Nathan Tumey |
